

## Emerging Drugs Poster Figure 3: Analysis of Emerging Drugs in Diluted Human Urine

Peaks	t <sub>R</sub> (min)	Precursor Ion	Product Ion	Product Ion
1. AB-FUBINACA	3.15	369.0	253.0	109.1
2. AB-PINACA	3.23	331.2	215.0	286.1
3. Salvinorin A	3.39	433.1	373.0	91.1
4. 5F-PB-22	4.04	377.2	232.1	143.9
5. PB-22	4.30	359.2	214.0	144.0
6. APINACA (AKB-48)	4.76	366.3	135.1	93.1

**Column** Raptor Biphenyl (cat.# 9309A5E)  
**Dimensions:** 50 mm x 3.0 mm ID  
**Particle Size:** 2.7 µm  
**Pore Size:** 90 Å  
**Guard Column:** Raptor Biphenyl EXP guard column cartridge 5 mm, 3 mm ID, 2.7 µm (cat.# 9309A0253)  
**Temp.:** 30 °C

**Sample**  
**Conc.:** 50 ng/mL in human urine and diluted 3x in a 0.2 µm PVDF Thomson SINGLE STEP filter vial with 50:50 water:methanol

**Inj. Vol.:** 2 µL

### Mobile Phase

**A:** 0.1% Formic acid in water  
**B:** 0.1% Formic acid in acetonitrile

Time (min)	Flow (mL/min)	%A	%B
0.00	0.6	75	25
1.00	0.6	75	25
5.00	0.6	5	95
5.50	0.6	5	95
5.51	0.6	75	25
7.00	0.6	75	25

**Max Pressure:** 400 bar  
**Detector** MS/MS  
**Ion Mode:** ESI+  
**Mode:** Scheduled MRM  
**Instrument** UHPLC

